Fig 1: Butyrate and propionate restore mRNA expression of EPC2 ALI cultures. A, mRNA expression of proinflammatory factor CCL26 and protease CAPN14 in IL-13-stimulated EPC2 ALI cultures treated with acetate (10 mM), propionate (10 mM), or butyrate (5 mM). B, mRNA expression of esophageal barrier proteins FLG and DSG1 in IL-13-stimulated EPC2 ALI cultures treated with acetate (10 mM), propionate (10 mM), or butyrate (5 mM). Data are representative of two to six independent experiments (n=3 wells/group). Outlier is shown as a separate data point. Data are presented as mean +SEM. Statistical significance was tested with one-way ANOVA followed by Dunnett's multiple comparisons test: *p<.05; **p<.01; ***p<.001; ****p<.0001; NS, not significant
Fig 2: Butyrate and propionate upregulate DSG1 and FLG protein expression in ALI cultures of EPC2 treated with IL-13. A, Immunofluorescent staining for barrier proteins DSG1 (left) and FLG (right) in red with a blue DAPI nuclear counterstain in IL-13-stimulated EPC2 ALI cultures treated with acetate (10 mM), propionate (10 mM), or butyrate (5 mM). Scale bar =50 µm. B, Quantification of DSG1 and FLG expression in IL-13-stimulated EPC2 ALI cultures treated with SCFA. Images in panel A are representative of three independent experiments performed in duplicate or triplicate and are taken at 40x magnification. Data in panel B are pooled from three independent experiments performed in duplicate or triplicate and are presented as mean +SEM. Statistical significance was tested with one-way ANOVA followed by Dunnett's multiple comparisons test: *p<.05, **p<.01; NS, not significant
Supplier Page from Abcam for Anti-Desmoglein 1/DSG1 antibody [EPR20382]